| Grant ID | CP130020 |
| Awarded On | February 19, 2014 |
| Title | Androgen Receptor N-Terminus Blocker Program for Prostate Cancer |
| Program | Product Development Research |
| Award Mechanism | Company Relocation |
| Institution/Organization | ESSA Pharma Inc. |
| Principal Investigator/Program Director | David Wood |
| Cancer Sites | Bone, Other, Prostate |
| Contracted Amount | $12,000,000 |
| Lay Summary |
ESSA Pharma Inc. (ESSA) intends to treat castrate-resistant prostate cancer (CRPC). Growth of prostate cancer cells is driven by male hormones. ESSA’s drugs block the hormone-fueled growth of prostate cancer tumors by an entirely novel mechanism. Specifically, our drugs covalently block the N-terminus of the androgen receptor, preventing activation of the receptor by any means. Thus our drugs may overcome all of the known mechanisms for hormone-therapy resistance. Our goal is that all men with recurrent prostate cancer will enjoy more months or even years of progression-free lifespan than current therapy offers. ESSA is currently in the clinical candidate selection stage, and expects to c... |